133 related articles for article (PubMed ID: 37884614)
1. Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?
Aoun F; Helou E; Albisinni S
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37884614
[No Abstract] [Full Text] [Related]
2. Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.
Bell MA; Campbell JD; Joice G; Sopko NA; Burnett AL
World J Mens Health; 2018 May; 36(2):103-109. PubMed ID: 29623698
[TBL] [Abstract][Full Text] [Related]
3. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
4. Completeness of prostate cancer staging in the Danish Cancer Registry, 2004-2009.
Nguyen-Nielsen M; Frøslev T; Friis S; Borre M; Harving N; Søgaard M
Clin Epidemiol; 2012; 4 Suppl 2(Suppl 2):17-23. PubMed ID: 22936853
[TBL] [Abstract][Full Text] [Related]
5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
7. Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer.
He W; Zhang F; Jiang F; Liu H; Wang G
BMC Urol; 2022 Nov; 22(1):195. PubMed ID: 36434610
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the dosimetric accuracy of the isocenter shifting method in prostate cancer patients with and without hip prostheses.
Hwang AB; Kinsey E; Xia P
Med Phys; 2009 Nov; 36(11):5221-7. PubMed ID: 19994532
[TBL] [Abstract][Full Text] [Related]
9. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma.
Eichelberger LE; Cheng L
Cancer; 2004 Jun; 100(12):2573-6. PubMed ID: 15197798
[TBL] [Abstract][Full Text] [Related]
10. Hormone-refractory prostate cancer: a shifting paradigm in treatment.
Gallagher E; Gapstur R
Clin J Oncol Nurs; 2006 Apr; 10(2):233-40. PubMed ID: 16708706
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer.
Fischer-Valuck BW; Baumann BC; Brown SA; Filson CP; Weiss A; Mueller R; Liu Y; Brenneman RJ; Sanda M; Michalski JM; Gay HA; James Rao Y; Pattaras JG; Jani AB; Hershatter B; Patel SA
Eur Urol Open Sci; 2022 Mar; 37():80-89. PubMed ID: 35243392
[TBL] [Abstract][Full Text] [Related]
13. A novel TNM staging system for gastric cancer based on the metro-ticket paradigm: a comparative study with the AJCC-TNM staging system.
Lu J; Zheng ZF; Wang W; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Zhou ZW; Huang CM; Zheng CH; Li P
Gastric Cancer; 2019 Jul; 22(4):759-768. PubMed ID: 30612230
[TBL] [Abstract][Full Text] [Related]
14. Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
Lawrance S; Bui C; Mahindra V; Arcorace M; Cooke-Yarborough C
BMC Cancer; 2019 Aug; 19(1):850. PubMed ID: 31462255
[TBL] [Abstract][Full Text] [Related]
15. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
16. A Novel TNM Classification for Colorectal Cancers based on the Metro-ticket Paradigm.
Pei JP; Zhang CD; Fu X; Ba Y; Yue S; Zhao ZM; Dai DQ
J Cancer; 2021; 12(11):3299-3306. PubMed ID: 33976739
[No Abstract] [Full Text] [Related]
17. Improvement in clinical TNM staging documentation within a prostate cancer quality improvement collaborative.
Filson CP; Boer B; Curry J; Linsell S; Ye Z; Montie JE; Miller DC
Urology; 2014 Apr; 83(4):781-6. PubMed ID: 24680448
[TBL] [Abstract][Full Text] [Related]
18. The TNM system of 1992. Comments from the TNM working group. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Chisholm GD; Hedlund PO; Adolfsson J; Denis LJ; Friberg S; Johansson JE; Peeling B
Scand J Urol Nephrol Suppl; 1994; 162():107-14; discussion 115-27. PubMed ID: 7529428
[TBL] [Abstract][Full Text] [Related]
19. [Incidental prostate cancer: volume, location and degree of differentiation of the tumor in the radical prostatectomy specimen and value of subclassification to stage A1 and A2].
Voges GE; McNeal JE; Stamey TA
Urologe A; 1991 Nov; 30(6):401-9. PubMed ID: 1722922
[TBL] [Abstract][Full Text] [Related]
20. Pathologic basis of focal therapy for early-stage prostate cancer.
Mouraviev V; Mayes JM; Polascik TJ
Nat Rev Urol; 2009 Apr; 6(4):205-15. PubMed ID: 19352395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
